A phase 3 trial of uproleselan in relapsed/refractory acute myeloid leukemia failed to meet the primary overall survival end ...

The 48-week end points of the MANIFEST-2 study show improvements in spleen reduction, symptoms, bone marrow fibrosis, and ...

Julio Chavez, MD, MS, discusses some of the important studies and research being presented at the 2024 American Society of ...

Long-term data from the pivotal phase 3 ELARA trial showed durable efficacy with tisagenlecleucel in high-risk follicular ...

Elizabeth A. Brem, MD, an assistant clinical professor in the Division of Hematology/Oncology, School of Medicine at the University of California, Irvine, discusses multiple types of therapies used in ...

Fatima Tuz Zahra, MD, discusses the methods and design of a retrospective analysis of 65 patients with acute myeloid leukemia ...

In response, Dave presents a study to be discussed at the 2024 American Society of Hematology (ASH) Annual Meeting and ...

Capivasertib combination shows promise in mHSPC vs the placebo combination, LBS-007 received fast track designation, and RP1 plus nivolumab submitted a BLA application. We also cover a retrospective ...

Nobel Prize in Chemistry highlights AI-driven breakthroughs in computational protein design and structure prediction. Tools ...

Francis P. Worden, MD, discusses how the effectiveness of lenvatinib in this real-world setting compares with results from ...

Patients with multiple myeloma face a complex, decades-long treatment journey involving care coordination, insurance ...

In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection ...